La Ricerca Traslazionale nelle neoplasie polmonari: stato dell’arte ed esperienze di ricerca

Pharmacogenomics of Lung Cancer, Parma, 27 November 2019

Presentation by Elisa Giovannetti at the congress “La Ricerca Traslazionale nelle neoplasie polmonari: stato dell’arte ed esperienze di ricerca”, co-organized by Prof. Tiseo and Prof. Petronini (Parma University).

And a special thank to Dr. Garajova and the organisers of the course “Pancreatic cancer: A multidisciplinary approach” at Parma AOUP, September 22th, 2019, with Dr. Francesco Leonardi, Dr. Raffaele Della Valle and Dr. Michele Milella (in the picture).

PDF file: Dr Giovannetti: Pharmacogenomics of Lung Cancer

Targeting SF3B1 as a novel therapeutic strategy against diffuse malignant peritoneal mesothelioma

Suprasplicesome meeting, Amsterdam, 23 September 2019

Presentation by Elisa Giovannetti: “Targeting SF3B1 as a novel therapeutic strategy against diffuse malignant peritoneal mesothelioma”

Presentation PDF: Targeting SF3B1 as a novel therapeutic strategy against diffuse malignant peritoneal mesothelioma

The results of this study have been published in EBiomedicine:
www.ebiomedicine.com/article/S2352-3964(18)30602-9
Article PDF: Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma
with a dedicated editorial: www.ncbi.nlm.nih.gov/pubmed/30612942

Proteomic profiling of gemcitabine-resistant pancreatic cancer cells unravels microtubule-associated protein 2 overexpression, that correlated to poorer survival but also to increased sensitivity to nab-paclitaxel

AISP 2019, Verona 21 September 2019

Presentation by Mjriam Capula, who was awarded for the Best Oral Presentation in preclinical/translational research

Some results of this study have been published in Therapeutic Advances in Medical Oncology:
www.ncbi.nlm.nih.gov/pmc/articles/10.1177_1758835919841233.pdf

PDF file: Mjriam Capula – Presentazione AISP 2019

Testimonianza

“Testimonianza” at the Course organized by the association “Women for Oncology” of the Italian and European Association of Medical Oncology (Host: Dr. L. Locati, Dr. M. Garassino), Montecitorio, Roma, Italy 18 June 2019

Link to the Italian association “Women for Oncology”: www.facebook.com/women4onco

PDF file: Testimonianza Giovannetti W40 2019

Tavola Rotonda Women for Oncology 2019

Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line

EORTC-PAMM Winter Meeting, Verona, Italy, 8th February 2019

Selected Oral presentation: “Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line”
By Dr. Alessandro Leonetti

The results of this study have been published in Biochemical Pharmacology:
www.ncbi.nlm.nih.gov/pubmed/31078602

PDF file: Decrease in p-PRAS40 plays a role in the synergy between erlotinib and crizotinib

Neighborhood matters: new tools and practical approaches for co-culturing cancer cells

Winter Meeting of the EORTC-PAMM 2019, Verona, Italy, 8th February 2019

Invited lecture at the Educational Course organized by the EORTC-PAMM group “Neighborhood matters: new tools and practical approaches for co-culturing cancer cells”

The discussion among students attending the course were published in the following articles in Anticancer Research:

• A Brief Guide to Performing Pharmacological Studies In Vitro: Reflections from the EORTC-PAMM Course “Preclinical and Early-phase Clinical Pharmacology”: www.ncbi.nlm.nih.gov/pubmed/31262863
• To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology: www.ncbi.nlm.nih.gov/pubmed/31262850
• Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology: www.ncbi.nlm.nih.gov/pubmed/31262864

PDF file: Neighborhood matters

Role of pharmacology in anticancer treatments

Symposium “Pharmacology forever”
Amsterdam, The Netherlands, 20th April 2018

Invited lecture “Role of pharmacology in anticancer treatments” by Elisa Giovannetti

PDF file: Role of pharmacology in anticancer treatments

Prospective study on the role of cytidine deaminase activity in lung cancer patients treated with gemcitabine-platinum-based chemotherapy

Winter Meeting of the EORTC-PAMM 2018, Roma, Italy, 7-10 February 2018

Oral presentation by Dr. Carmelo Tibaldi: Prospective study on the role of cytidine deaminase activity in lung cancer patients treated with gemcitabine-platinum-based chemotherapy.
Tibaldi C, Camerini A, Tiseo M,  Mazzoni F, Barbieri F, Vittimberga I, Brighenti M, Boni L, Baldini E, Honeywell R, Chartoire M,  Peters GJ, Giovannetti E.

The results of this study have been published in British Journal of Cancer:
www.ncbi.nlm.nih.gov/pubmed/30405211

Moreover we wrote a commentary on CDA activity in British Journal of Clinical Pharmacology:
www.bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.13921

PDF file: Prospective study on the role of cytidine deaminase activity

Optimizing immunotherapy: Rationale for a combination therapy approach

ESMO 2017: ESMO COLLOQUIUM

Optimizing immunotherapy: Rationale for a combination therapy approach
Invited Oral Presentation at the annual meeting of the European Society of Medical Oncology (ESMO) Congress, Madrid, September 2017

A review focusing on some of these studies has been published in Drug Resistance Updates: Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer

Link: www.sciencedirect.com/science/article/pii/S1368764619300330

PDF file: ESMO 2017

Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing

European Pancreatic Club (EPC) Congress, Budapest, June 2017

The results of this study have been published in Scientific Reports:
www.nature.com/articles/srep44686

Pdf: Development of bioluminescent chick chorioallantoic membrane (CAM) models

Photo with our collaborators, including Dr. Le Large and Dr. Meijer (VUmc, Amsterdam), Dr. Frampton and Dr. Mato Prado (Imperial College London)

Phospho-AKT: a potential resistance marker to chemotherapy and therapy-target to restore sensitivity in pancreatic cancer

AISP, Roma, October 2016
Presentation by Dr. Daniela Massihnia

The results of this study have been published in Journal of Hematology and Oncology:
www.ncbi.nlm.nih.gov/pmc/articles/PMC5219723

Pdf: Phospho-AKT a potential resistance marker

The results of her studies have been published in the following review and scientific paper:
www.ncbi.nlm.nih.gov/pubmed/27610011
www.ncbi.nlm.nih.gov/pubmed/30394883

Cancer Pharmacology Lab group photo, including Dr. Chiara Caparello won the award for the best oral presentation

Resistance mechanisms in new drugs and how to overcome it: the point of view of the pharmacologist

Elisa Giovannetti
Cancer Pharmacology Lab, Pisa University, Italy
Lab Medical Oncology, Vumc, Amsterdam, The Netherlands

37th EORTC-PAMM Winter Meeting
Antwerp, Belgium
11 February 2016

Pdf: Resistance mechanisms in new drugs and how to overcome it

Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells

Leticia G. Leon
PhD, PharmD

37th EORTC-PAMM Winter Meeting
Antwerp, Belgium
10 February 2016

Pdf: Synergistic activity of the c-Met and tubulin inhibitor tivantinib

Il mestiere del ricercatore

Elisa Giovannetti
Azienda Ospedaliera Universitaria di Pisa

Coloro che ritengono di essere “perfetti” non potranno mai progredire, mentre chi ha la coscienza della propria “imperfezione” è costantemente affetto da curiosità e tensione verso il miglioramento, fondamentali per fare nuove scoperte
– Rita Levi Montalcini

Incontri con la Ricerca
Aula Magna – Centro Congressi Polo Fibonacci
4 Novembre 2015

Pdf: Il mestire del ricercatore

Association of AKT1 and SELP Polymorphisms with Cachexia and Survival of Patients with Pancreatic Cancer

Paola Pace, Abolfazl Avan, Andrea Mambrini, Niccola Funel, Tessa Y. Le Large, Maurizio Cantore, Ugo Boggi, Elisa Giovannetti

Carrara Civic Hospital; VU University Medical Center, Amsterdam, The Netherlands; Cancer Pharmacology Lab, AIRC/Start Up Unit, Pisa; Mantova Civic Hospital; University of Pisa and Istituto Toscano Tumori

Congresso Nazionale AISP 2015
October 22, 2015 – Milano (Italy)

Pdf: AISP 2015 – Cachexia

Foto:

16th World Conference on Lung Cancer

September 6-9, 2015 – Denver, Colorado, USA

MicroRNA Profiling of a Familial Primary Pulmonary Enteric Adenocarcinoma

Ingrid Garajová, Niccola Funel, Michelangelo Fiorentino, Valentina Agostini, Manuela Ferracin, Massimo Negrini, Giovanni Luca Frassineti, Christian Rolf, Guido Biasco, Elisa Giovannetti

Website: www.iaslc.org

Pdf: Garajová at 16th World Conference on Lung Cancer

10th Annual Scientific conference of Istituto Toscano Tumori (ITT)

July 1-3, 2015 – Pisa (Italy)

Molecular basis of progression in pancreatic cancer

Niccola Funel

Website: www.ittumori.it

Pdf: Funel at 10th Annual Scientific conference of ITT

47th Meeting of European Pancreatic Club

The Cancer Pharmacology Lab was under the spotlight at the Annual Meeting of the European Pancreatic Club, in Toledo, Spain, 24-26 June 2015

The abstract “Galectin-4 (Gal-4) expression is associated with reduced lymph node metastasis, and the modulation of its downstream pathway Wnt/beta-catenin inhibits invasive behavior of pancreatic cancer (PDAC) cells” was selected as an oral presentation, and presented by Dr. Niccola Funel in the session “Pancreatic Ductal Adenocarcinoma”
During the Gala Dinner, the EPC acknowledged the work of Dr. Giovannetti as an elected Abstract Selection Committee member in the period 2012-2015, giving her the EPC medallion.

Hypoexpression of Galectin-4 inhibits invasive behavior of Primary Pancreatic Adenocarcinoma Cells and is associated with modulation of Wnt/β-catenin Signalling and reduced Lymph Node Metastasis

Niccola Funel
Maftouh M, Belo AI, Avan A, Funel N, Peters GJ, van Die I, Giovannetti E.

Department of Translational Research and The New Technologies in Medicine and Surgery
AIRC-Start-Up, Pisa, Italy

Website: www.epc2015.net

Pdf: Funel at 47th Meeting of European Pancreatic Club

Photos:

16th International Symposium on Purine and Pyrimidine Metabolism in Man

June 6-9, 2015 – Columbia University, New York City

Inhibitors of lactate dehydrogenase overcome the resistance towards gemcitabine in hypoxic mesothelioma cells, and modulate the expression of the human equilibrative transporter-1 (hENT1)

Elisa Giovannetti, Leticia G. Leon, Paolo A. Zucali, Filippo Minutolo, Godefridus J Peters

This work was partially supported by grants from “The Law Offices of Peter G. Angelos Grant” from the Mesothelioma Applied Research Foundation (E.G, L.G.L, F.M., G.J.P), EORTC-PAMM (G.J.P, E.G., F.M.), “Clinical Research and Innovation – scouting” from the University of Pisa (E.G., F.M.), Fondazione Humanitas (E.G, P.A.Z), AIRC/Start-Up (E.G.), European Union Seventh Framework Program [FP7/2007-2013] under grant agreement n° PIIF-GA-2011-299026 (F.M.), and FP7-REGPOT-2012-CT2012-31637-IMBRAIN (L.G.L., E.G., G.J.P.)

Website: www.pps2015.org

Pdf: Inhibitors at 16th International Symposium PPS

AIRC Start-Up Meeting 2015

June 5, 2015 – Verona (Italy)

Bioluminescent pancreatic cancer mouse models from genetically characterized primary cells: a platform for drug discovery

Elisa Giovannetti, MD, PhD
Azienda Ospedaliera Universitaria Pisana

Pdf: Giovannetti at AIRC Start-Up Meeting 2015